GSK drops out of Vertex pact for HIV therapy

GlaxoSmithKline has dropped out of its pact with Vertex to develop the experimental HIV drug brecanavir, saying it will be too difficult to develop the proper formulation of the drug. The therapy is in mid-stage trials. Vertex notes that the two companies have been collaborating since 1993 and have developed two approved therapies for HIV.

- here's the AP report on GSK's move

Related Article:
Vertex shares jump on hep C trial data. Report